5-(5-bromothiophen-2-yl)pyrimidine | 71637-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-(5-bromothiophen-2-yl)pyrimidine
• 英文别名: 5-(5'-Brom-2-thienyl)pyrimidin；5-(5-Bromo-2-thienyl)pyrimidine
• CAS: 71637-39-3
• 化学式: C₈H₅BrN₂S
• 分子量: 241.111
• InChiKey: MVPVHUNJWQWPFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-(thiophen-2-yl)pyrimidine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以74%的产率得到5-(5-bromothiophen-2-yl)pyrimidine
  参考文献：
  名称：

  作为一个新的抗分枝杆菌化合物家族，C（4）和/或C（5）噻吩基取代的嘧啶的合成及其与结构-活性的关系

  摘要：

  铃木交叉偶联和亲核氢取代的结合（小号ñH）反应被证明是从市售的5-溴嘧啶合成C（4）和/或C（5）单（噻吩基）和二（噻吩基）取代的嘧啶的简便方法。所有新的嘧啶被发现是在微摩尔浓度的活性在体外针对ħ 37 RV，鸟，terrae，利福平的和异烟肼耐药的菌株结核分枝杆菌。对于这些化合物，已经获得了小鼠急性体内毒性的数据，这些化合物似乎是有希望的抗结核药。

  DOI：

  10.1016/j.ejmech.2015.05.007

文献信息

• LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Umemura Eijirou

  公开号：US20100184746A1

  公开（公告）日：2010-07-22

  An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R 1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R 1 represents aryl or a five- or six-membered monocyclic heterocyclic group; R 2 represents a hydrogen atom or C 1-6 alkyl; R 3 represents C 1-6 alkyl or C 3-6 cycloalkyl-C 1-4 alkyl; R 4 , R 5 , and R 6 represent a hydrogen atom; R 7 represents C 1-6 alkyl; and m is 1 to 3. The compounds are novel lincosamide derivatives that have a potent activity against resistant Streptococcus pneumoniae . Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目标是提供式（I）的化合物或其药理学上可接受的盐或溶剂，其中A代表芳基，而R1代表五元或六元单环杂环基，或A代表四至六元单环杂环基，而R1代表芳基或五元或六元单环杂环基；R2代表氢原子或C1-6烷基；R3代表C1-6烷基或C3-6环烷基-C1-4烷基；R4、R5和R6代表氢原子；R7代表C1-6烷基；m为1至3。这些化合物是新型的林可霉素衍生物，对耐药性肺炎链球菌具有强效活性。此外，这些化合物可用作抗微生物剂，对预防或治疗细菌感染性疾病有用。
• LINCOSAMIDE DERIVATIVE, AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Meiji Seika Kaisha Ltd.

  公开号：EP2166015A1

  公开（公告）日：2010-03-24

  An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R1 represents aryl or a five- or six-membered monocyclic heterocyclic group; R2 represents a hydrogen atom or C1-6 alkyl; R3 represents C1-6 alkyl or C3-6 cycloalkyl-C1-4 alkyl; R4, R5, and R6 represent a hydrogen atom; R7 represents C1-6 alkyl; and m is 1 to 3. The compounds are novel lincosamide derivatives that have a potent activity against resistant Streptococcus pneumoniae. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目的是提供式(I)化合物或其药理学上可接受的盐或溶液，其中 A 代表芳基，而 R1 代表五元或六元单环杂环基团，或 A 代表四至六元单环杂环基团，而 R1 代表芳基或五元或六元单环杂环基团；R2代表氢原子或C1-6烷基；R3代表C1-6烷基或C3-6环烷基-C1-4烷基；R4、R5和R6代表氢原子；R7代表C1-6烷基；m为1至3。这些化合物是新型林可酰胺衍生物，对耐药性肺炎链球菌具有强效活性。此外，这些化合物还可用作抗菌剂，用于预防或治疗细菌感染性疾病。
• GRONOWITZ S.; LILJEFORS S., CHEM. SCR., 1978-1979, 13, NO 1, 39-45
  作者：GRONOWITZ S.、 LILJEFORS S.

  DOI：——

  日期：——
• US7867980B2
  申请人：——

  公开号：US7867980B2

  公开（公告）日：2011-01-11
• Synthesis, and structure–activity relationship for C(4) and/or C(5) thienyl substituted pyrimidines, as a new family of antimycobacterial compounds
  作者：Egor V. Verbitskiy、Ekaterina M. Cheprakova、Pavel A. Slepukhin、Marionella A. Kravchenko、Sergey N. Skornyakov、Gennady L. Rusinov、Oleg N. Chupakhin、Valery N. Charushin

  DOI：10.1016/j.ejmech.2015.05.007

  日期：2015.6

  Combination of the Suzuki cross-coupling and nucleophilic aromatic substitution of hydrogen (SNH) reactions proved to be a convenient method for the synthesis of C(4) and/or C(5) mono(thienyl) and di(thienyl) substituted pyrimidines from commercially available 5-bromopyrimidine. All new pyrimidines were found to be active in micromolar concentrations in vitro against H37Rv, avium, terrae, rifampicin

  铃木交叉偶联和亲核氢取代的结合（小号ñH）反应被证明是从市售的5-溴嘧啶合成C（4）和/或C（5）单（噻吩基）和二（噻吩基）取代的嘧啶的简便方法。所有新的嘧啶被发现是在微摩尔浓度的活性在体外针对ħ 37 RV，鸟，terrae，利福平的和异烟肼耐药的菌株结核分枝杆菌。对于这些化合物，已经获得了小鼠急性体内毒性的数据，这些化合物似乎是有希望的抗结核药。